Business briefs: Layoffs at Roche and Merck, plus pipeline news

Merck and Roche Diagnostics announce job cuts; Novartis abandons an Afinitor study; an FDA advisory committee gives Bayer's lung drug the nod; Vivus still has no plans for Qsymia DTC; and Isis drops development of a mid-stage RA drug

Roche's Rituxan successor receives high marks


Genentech's blockbuster follow-up shows promise in preliminary Phase III data

Tarceva diagnostic brings new indication

Tarceva diagnostic brings new indication


Tarceva picks up a first-line indication and a companion diagnostic

Email Newsletters

MM&M Future Leaders

Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.